Next Investors logo grey
  1. Home
  2. Phase Iii Clinical Trials

Phase Iii Clinical Trials

What could commercialisation actually look like for DXB?

Next Investors Mar 06, 2023

The sparsentan drug, which recently received accelerated FDA approval, and priced at US$120,000 per year, per patient, could act as a benchmark for Dimerix (ASX:DXB) pricing and potential deal value in negotiations with major pharmaceutical companies.

DXB to run a Phase III COVID-19 Study in Australia

Finfeed Oct 15, 2021

Dimerix (ASX:DXB) is moving fast with its Covid-19 trials, and today announced that this COVID-19 Phase III Study will expand to Australia.

DXB announces approval for Phase III COVID-19 trials

Next Investors Sep 27, 2021

On Friday last week, DXB announced that the main drug regulator in India has recommended approval for DXB’s Phase III clinical trials on COVID-19 treatment, specifically for patients with respiratory complications intended for hospitalisation — its CLARITY 2.0 study.

DXB announces approval for Phase III COVID-19 trials in India

Finfeed Sep 24, 2021

The main drug regulator in India has recommended approval for Dimerix Ltd's (ASX:DXB) Phase 3 clinical trials on its COVID-19 treatment for patients with respiratory complications.

DXB kicks off Phase 3 clinical trials - Ethics approval lodged

Finfeed Aug 26, 2021

Yesterday Dimerix (ASX:DXB) announced its first “ethics submission” in Australia. Once approved, the patient recruitment process can begin for the Phase 3 trials. We will provide our commentary at every step in the process.

The first investment in our new early stage, ASX listed biotech portfolio

Finfeed Aug 16, 2021

Everything that you need to know about investing in Dimerix (ASX:DXB). A comprehensive summary of 9 reasons why we have invested in DXB. Upcoming projects, and milestones.

Join Our
Mailing List